Zhang X X, Guo J S
Division of Digestive Diseases, Zhongshan Hospital, Shanghai Institute of Liver Diseases, Fudan University, Shanghai 200032, China.
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):923-928. doi: 10.3760/cma.j.issn.1007-3418.2019.12.004.
Portal hypertension is the major cause of complications in decompensated liver cirrhosis. Research results showed that non-selective β-blockers, angiotensin receptor antagonists, and statins can improve portal hypertension by reducing portal vein blood flow and intrahepatic resistance, and have certain prevention and treatment effect on hemodynamic disorders and portal hypertensive complications in chronic liver diseases. Herein, we review the mechanism of action, clinical effects and limitations of these three types of drugs on portal hypertension of cirrhosis.
门静脉高压是失代偿期肝硬化并发症的主要原因。研究结果表明，非选择性β受体阻滞剂、血管紧张素受体拮抗剂和他汀类药物可通过减少门静脉血流和肝内阻力来改善门静脉高压，对慢性肝病的血流动力学紊乱和门静脉高压并发症具有一定的防治作用。在此，我们综述这三类药物对肝硬化门静脉高压的作用机制、临床疗效及局限性。
Zotero 插件